Study offers new insight for preventing fear relapse after trauma

November 29, 2011 by Jared Wadley, University of Michigan

(Medical Xpress) -- In a new study, University of Michigan researchers identified brain circuits in rats that are responsible for the return of fear after it has been suppressed behaviorally.

The findings involve a process called , which is at the heart of for such as post-traumatic stress disorder. During extinction, the repeated exposure of a feared stimulus gradually decreases anxiety. For example, this approach is commonly used to treat in .

Extinction does not erase the original memory, but yields a "safety" memory that inhibits fear under certain conditions. Unfortunately, these "safety" memories are short-lived and place-dependent, says Stephen Maren, U-M professor of psychology and neuroscience. Individuals that undergo extinction-based therapies often exhibit relapse of fear.

Maren and his colleagues studied how fear and safety memories are retrieved by a network of three brain structures that are critical for memory and emotion—the hippocampus, prefrontal cortex and amygdala.

Rats that had been conditioned to fear an auditory stimulus by associating it with a mild shock decreased their fear when the stimulus was extinguished. This fear returned, however, when the stimulus was encountered in a place that was different from where the extinction procedure occurred. This is similar to the return of fear patients undergoing exposure therapy experience when they leave the clinic.

Researchers examined the rats' brains to determine how the fear memory network changed when fear returned. The researchers found that the return of fear activated neurons in the hippocampus and prefrontal cortex that project to the amygdala. Next, they found that severing the connections between these structures prevented fear relapse.

The results provide new insight into the brain systems involved in the return of fear memories thought to be vanquished by extinction. Developing novel therapeutic approaches that dampens activity in these circuits might aid in preventing fear relapse after therapy.

The findings appear in current issue of the Journal of Neuroscience.

Explore further: Regulating the formation of fear extinction memory

Related Stories

Regulating the formation of fear extinction memory

August 15, 2011
(Medical Xpress) -- Neuroscientists at UQ's Queensland Brain Institute have discovered a previously unrecognized layer of gene regulation associated with fear extinction.

Recommended for you

Dopamine's yin-yang personality: It's an upper and a downer

December 10, 2018
For decades, psychologists have viewed the neurotransmitter dopamine as a double-edged sword: released in the brain as a reward to train us to seek out pleasurable experiences, but also a "drug" the constant pursuit of which ...

Brainwaves suppress obvious ideas to help us think more creatively

December 10, 2018
The human brain needs to suppress obvious ideas in order to reach the most creative ones, according to scientists at Queen Mary University of London and Goldsmiths, University of London.

Regrowing damaged nerves hinges on shutting down key genes

December 10, 2018
Neurons in the brain and spinal cord don't grow back after injury, unlike those in the rest of the body. Cut your finger, and you'll probably be back to using it in days or weeks; slice through your spinal cord, and you likely ...

Editing consciousness: How bereaved people control their thoughts without knowing it

December 10, 2018
People who are grieving a major loss, such as the death of a spouse or a child, use different coping mechanisms to carry on with their lives. Psychologists have been able to track different approaches, which can reflect different ...

Team seeks to create genetic map of worm's nervous system

December 10, 2018
How do you build a brain? What "rules" govern where neurons end up, how they connect to each other, and which functions they perform?

Ezogabine treatment shown to reduce motor neuron excitability in ALS patients

December 10, 2018
Brian Wainger, MD, Ph.D., of the Healey Center for ALS at Massachusetts General Hospital (MGH) presented initial, top-level results of a recently completed phase 2 clinical trial of ezogabine (also called retigabine) on December ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.